Jan van Zelst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jan van Zelst has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Ritse M. Mann
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
15 shared publications Nico Karssemeijer
Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, the Netherlands
11 shared publicationsTao Tan
Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, the Netherlands
5 shared publicationsBram Platel
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen 6525 GA, The Netherlands
4 shared publications- Peter Bult
Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands
3 shared publications Suzan Vreemann
From the Departments of Radiology and Nuclear Medicine (J.C.M.v.Z., R.D.M.M., S.V., N.K., R.M.M.), Human Genetics (G.W., N.H.), and Pathology (P.B.), Radboud University Medical Centre, Route 766, Geert Grooteplein 10, 6525GA Nijmegen, the Netherlands; and Department of Radiology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands (M.J.C.M.R., M.d.J.).
3 shared publications
Latest Publications
- Open Access
- 19 July 2019
- Published by SAGE Publications in Acta Radiologica
- Vol. 61 (3) , 312-320
Validation of radiologists’ findings by computer-aided detection (CAD) software in breast cancer detection with automated 3D breast ultrasound: a concept study in implementation of artificial intelligence software
Background: Computer-aided detection software for automated breast ultrasound has been shown to have potential in improving the accuracy of radiologists. Alternative ways of implementing computer-aided detection, such as independent validation or preselecting suspicious cases, might also improve radiologists’ accuracy. Purpose: To investigate the effect of using computer-aided detection software to improve the performance of radiologists by validating findings reported by radiologists during screening with automated breast ultrasound. Material and Methods: Unilateral automated breast ultrasound exams were performed in 120 women with dense breasts that included 60 randomly selected normal exams, 30 exams with benign lesions, and 30 malignant cases (20 mammography-negative). Eight radiologists were instructed to detect breast cancer and rate lesions using BI-RADS and level-of-suspiciousness scores. Computer-aided detection software was used to check the validity of radiologists' findings. Findings found negative by computer-aided detection were not included in the readers’ performance analysis; however, the nature of these findings were further analyzed. The area under the curve and the partial area under the curve for an interval in the range of 80%–100% specificity before and after validation of computer-aided detection were compared. Sensitivity was computed for all readers at a simulation of 90% specificity. Results: Partial AUC improved significantly from 0.126 (95% confidence interval [CI] = 0.098–0.153) to 0.142 (95% CI = 0.115–0.169) ( P = 0.037) after computer-aided detection rejected mostly benign lesions and normal tissue scored BI-RADS 3 or 4. The full areas under the curve (0.823 vs. 0.833, respectively) were not significantly different ( P = 0.743). Four cancers detected by readers were completely missed by computer-aided detection and four other cancers were detected by both readers and computer-aided detection but falsely rejected due to technical limitations of our implementation of computer-aided detection validation. In this study, validation of computer-aided detection discarded 42.6% of findings that were scored BI-RADS ≥3 by the radiologists, of which 85.5% were non-malignant findings. Conclusion: Validation of radiologists’ findings using computer-aided detection software for automated breast ultrasound has the potential to improve the performance of radiologists. Validation of computer-aided detection might be an efficient tool for double-reading strategies by limiting the amount of discordant cases needed to be double-read.
- 19 July 2019
- Published by SAGE Publications in Acta Radiologica
- Vol. 61 (3) , 312-320
Open AccessValidation of radiologists’ findings by computer-aided detection (CAD) software in breast cancer detection with automated 3D breast ultrasound: a concept study in implementation of artificial intelligence software
Background: Computer-aided detection software for automated breast ultrasound has been shown to have potential in improving the accuracy of radiologists. Alternative ways of implementing computer-aided detection, such as independent validation or preselecting suspicious cases, might also improve radiologists’ accuracy. Purpose: To investigate the effect of using computer-aided detection software to improve the performance of radiologists by validating findings reported by radiologists during screening with automated breast ultrasound. Material and Methods: Unilateral automated breast ultrasound exams were performed in 120 women with dense breasts that included 60 randomly selected normal exams, 30 exams with benign lesions, and 30 malignant cases (20 mammography-negative). Eight radiologists were instructed to detect breast cancer and rate lesions using BI-RADS and level-of-suspiciousness scores. Computer-aided detection software was used to check the validity of radiologists' findings. Findings found negative by computer-aided detection were not included in the readers’ performance analysis; however, the nature of these findings were further analyzed. The area under the curve and the partial area under the curve for an interval in the range of 80%–100% specificity before and after validation of computer-aided detection were compared. Sensitivity was computed for all readers at a simulation of 90% specificity. Results: Partial AUC improved significantly from 0.126 (95% confidence interval [CI] = 0.098–0.153) to 0.142 (95% CI = 0.115–0.169) ( P = 0.037) after computer-aided detection rejected mostly benign lesions and normal tissue scored BI-RADS 3 or 4. The full areas under the curve (0.823 vs. 0.833, respectively) were not significantly different ( P = 0.743). Four cancers detected by readers were completely missed by computer-aided detection and four other cancers were detected by both readers and computer-aided detection but falsely rejected due to technical limitations of our implementation of computer-aided detection validation. In this study, validation of computer-aided detection discarded 42.6% of findings that were scored BI-RADS ≥3 by the radiologists, of which 85.5% were non-malignant findings. Conclusion: Validation of radiologists’ findings using computer-aided detection software for automated breast ultrasound has the potential to improve the performance of radiologists. Validation of computer-aided detection might be an efficient tool for double-reading strategies by limiting the amount of discordant cases needed to be double-read.
- 1 October 2018
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 53 (10) , 579-586
Multireader Study on the Diagnostic Accuracy of Ultrafast Breast Magnetic Resonance Imaging for Breast Cancer Screening
Objectives: Breast cancer screening using magnetic resonance imaging (MRI) has limited accessibility due to high costs of breast MRI. Ultrafast dynamic contrast-enhanced breast MRI can be acquired within 2 minutes. We aimed to assess whether screening performance of breast radiologist using an ultrafast breast MRI-only screening protocol is as good as performance using a full multiparametric diagnostic MRI protocol (FDP). Materials and Methods: The institutional review board approved this study, and waived the need for informed consent. Between January 2012 and June 2014, 1791 consecutive breast cancer screening examinations from 954 women with a lifetime risk of more than 20% were prospectively collected. All women were scanned using a 3 T protocol interleaving ultrafast breast MRI acquisitions in a full multiparametric diagnostic MRI protocol consisting of standard dynamic contrast-enhanced sequences, diffusion-weighted imaging, and T2-weighted imaging. Subsequently, a case set was created including all biopsied screen-detected lesions in this period (31 malignant and 54 benign) and 116 randomly selected normal cases with more than 2 years of follow-up. Prior examinations were included when available. Seven dedicated breast radiologists read all 201 examinations and 153 available priors once using the FDP and once using ultrafast breast MRI only in 2 counterbalanced and crossed-over reading sessions. Results: For reading the FDP versus ultrafast breast MRI alone, sensitivity was 0.86 (95% confidence interval [CI], 0.81–0.90) versus 0.84 (95% CI, 0.78–0.88) (P = 0.50), specificity was 0.76 (95% CI, 0.74–0.79) versus 0.82 (95% CI, 0.79–0.84) (P = 0.002), positive predictive value was 0.40 (95% CI, 0.36–0.45) versus 0.45 (95% CI, 0.41–0.50) (P = 0.14), and area under the receiver operating characteristics curve was 0.89 (95% CI, 0.82–0.96) versus 0.89 (95% CI, 0.82–0.96) (P = 0.83). Ultrafast breast MRI reading was 22.8% faster than reading FDP (P < 0.001). Interreader agreement is significantly better for ultrafast breast MRI (κ = 0.730; 95% CI, 0.699–0.761) than for the FDP (κ = 0.665; 95% CI, 0.633–0.696). Conclusions: Breast MRI screening using only an ultrafast breast MRI protocol is noninferior to screening with an FDP and may result in significantly higher screening specificity and shorter reading time.
- 1 October 2018
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 53 (10) , 579-586
Multireader Study on the Diagnostic Accuracy of Ultrafast Breast Magnetic Resonance Imaging for Breast Cancer Screening
Objectives: Breast cancer screening using magnetic resonance imaging (MRI) has limited accessibility due to high costs of breast MRI. Ultrafast dynamic contrast-enhanced breast MRI can be acquired within 2 minutes. We aimed to assess whether screening performance of breast radiologist using an ultrafast breast MRI-only screening protocol is as good as performance using a full multiparametric diagnostic MRI protocol (FDP). Materials and Methods: The institutional review board approved this study, and waived the need for informed consent. Between January 2012 and June 2014, 1791 consecutive breast cancer screening examinations from 954 women with a lifetime risk of more than 20% were prospectively collected. All women were scanned using a 3 T protocol interleaving ultrafast breast MRI acquisitions in a full multiparametric diagnostic MRI protocol consisting of standard dynamic contrast-enhanced sequences, diffusion-weighted imaging, and T2-weighted imaging. Subsequently, a case set was created including all biopsied screen-detected lesions in this period (31 malignant and 54 benign) and 116 randomly selected normal cases with more than 2 years of follow-up. Prior examinations were included when available. Seven dedicated breast radiologists read all 201 examinations and 153 available priors once using the FDP and once using ultrafast breast MRI only in 2 counterbalanced and crossed-over reading sessions. Results: For reading the FDP versus ultrafast breast MRI alone, sensitivity was 0.86 (95% confidence interval [CI], 0.81–0.90) versus 0.84 (95% CI, 0.78–0.88) (P = 0.50), specificity was 0.76 (95% CI, 0.74–0.79) versus 0.82 (95% CI, 0.79–0.84) (P = 0.002), positive predictive value was 0.40 (95% CI, 0.36–0.45) versus 0.45 (95% CI, 0.41–0.50) (P = 0.14), and area under the receiver operating characteristics curve was 0.89 (95% CI, 0.82–0.96) versus 0.89 (95% CI, 0.82–0.96) (P = 0.83). Ultrafast breast MRI reading was 22.8% faster than reading FDP (P < 0.001). Interreader agreement is significantly better for ultrafast breast MRI (κ = 0.730; 95% CI, 0.699–0.761) than for the FDP (κ = 0.665; 95% CI, 0.633–0.696). Conclusions: Breast MRI screening using only an ultrafast breast MRI protocol is noninferior to screening with an FDP and may result in significantly higher screening specificity and shorter reading time.
- Open Access
- 3 August 2018
- Published by Springer Nature in Breast Cancer Research
- Vol. 20 (1) , 1-12
The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI
Breast magnetic resonance imaging (MRI) is the most sensitive imaging method for breast cancer detection and is therefore offered as a screening technique to women at increased risk of developing breast cancer. However, mammography is currently added from the age of 30 without proven benefits. The purpose of this study is to investigate the added cancer detection of mammography when breast MRI is available, focusing on the value in women with and without BRCA mutation, and in the age groups above and below 50 years. This retrospective single-center study evaluated 6553 screening rounds in 2026 women at increased risk of breast cancer (1 January 2003 to 1 January 2014). Risk category (BRCA mutation versus others at increased risk of breast cancer), age at examination, recall, biopsy, and histopathological diagnosis were recorded. Cancer yield, false positive recall rate (FPR), and false positive biopsy rate (FPB) were calculated using generalized estimating equations for separate age categories (< 40, 40–50, 50–60, ≥ 60 years). Numbers of screens needed to detect an additional breast cancer with mammography (NSN) were calculated for the subgroups. Of a total of 125 screen-detected breast cancers, 112 were detected by MRI and 66 by mammography: 13 cancers were solely detected by mammography, including 8 cases of ductal carcinoma in situ. In BRCA mutation carriers, 3 of 61 cancers were detected only on mammography, while in other women 10 of 64 cases were detected with mammography alone. While 77% of mammography-detected-only cancers were detected in women ≥ 50 years of age, mammography also added more to the FPR in these women. Below 50 years the number of mammographic examinations needed to find an MRI-occult cancer was 1427. Mammography is of limited added value in terms of cancer detection when breast MRI is available for women of all ages who are at increased risk. While the benefit appears slightly larger in women over 50 years of age without BRCA mutation, there is also a substantial increase in false positive findings in these women.
- 3 August 2018
- Published by Springer Nature in Breast Cancer Research
- Vol. 20 (1) , 1-12
Open AccessThe added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI
Breast magnetic resonance imaging (MRI) is the most sensitive imaging method for breast cancer detection and is therefore offered as a screening technique to women at increased risk of developing breast cancer. However, mammography is currently added from the age of 30 without proven benefits. The purpose of this study is to investigate the added cancer detection of mammography when breast MRI is available, focusing on the value in women with and without BRCA mutation, and in the age groups above and below 50 years. This retrospective single-center study evaluated 6553 screening rounds in 2026 women at increased risk of breast cancer (1 January 2003 to 1 January 2014). Risk category (BRCA mutation versus others at increased risk of breast cancer), age at examination, recall, biopsy, and histopathological diagnosis were recorded. Cancer yield, false positive recall rate (FPR), and false positive biopsy rate (FPB) were calculated using generalized estimating equations for separate age categories (< 40, 40–50, 50–60, ≥ 60 years). Numbers of screens needed to detect an additional breast cancer with mammography (NSN) were calculated for the subgroups. Of a total of 125 screen-detected breast cancers, 112 were detected by MRI and 66 by mammography: 13 cancers were solely detected by mammography, including 8 cases of ductal carcinoma in situ. In BRCA mutation carriers, 3 of 61 cancers were detected only on mammography, while in other women 10 of 64 cases were detected with mammography alone. While 77% of mammography-detected-only cancers were detected in women ≥ 50 years of age, mammography also added more to the FPR in these women. Below 50 years the number of mammographic examinations needed to find an MRI-occult cancer was 1427. Mammography is of limited added value in terms of cancer detection when breast MRI is available for women of all ages who are at increased risk. While the benefit appears slightly larger in women over 50 years of age without BRCA mutation, there is also a substantial increase in false positive findings in these women.
- 1 May 2018
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 38 (3) , 663-683
Automated Three-dimensional Breast US for Screening: Technique, Artifacts, and Lesion Characterization
Automated breast (AB) ultrasonography (US) scanners have recently been brought to market for breast imaging. AB US devices use mechanically driven wide linear-array transducers that can image whole-breast US volumes in three dimensions. AB US is proposed for screening as a supplemental modality to mammography in women with dense breasts and overcomes important limitations of whole-breast US using handheld devices, such as operator dependence and limited reproducibility. A literature review of supplemental whole-breast US for screening was performed, which showed that both AB US and handheld US allow detection of mammographically negative early-stage invasive breast cancers but also increase the false-positive recall rate. Technicians with limited training can perform AB US; nevertheless, there is a learning curve for acquiring optimal images. Proper acquisition technique may allow avoidance of common artifacts that could impair interpretation of AB US results. Regardless, interpretation of AB US results can be challenging. This article reviews the US appearance of common benign and malignant lesions and presents examples of false-positive and false-negative AB US results. In situ breast cancers are rarely detected with supplemental whole-breast US. The most discriminating feature that separates AB US from handheld US is the retraction phenomenon on coronal reformatted images. The retraction phenomenon is rarely seen with benign findings but accompanies almost all breast cancers. In conclusion, women with dense breasts may benefit from supplemental AB US examinations. Understanding the pitfalls in acquisition technique and lesion interpretation, both of which can lead to false-positive recalls, might reduce the potential harm of performing supplemental AB US. Online supplemental material is available for this article. ©RSNA, 2018.
- 1 May 2018
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 38 (3) , 663-683
Automated Three-dimensional Breast US for Screening: Technique, Artifacts, and Lesion Characterization
Automated breast (AB) ultrasonography (US) scanners have recently been brought to market for breast imaging. AB US devices use mechanically driven wide linear-array transducers that can image whole-breast US volumes in three dimensions. AB US is proposed for screening as a supplemental modality to mammography in women with dense breasts and overcomes important limitations of whole-breast US using handheld devices, such as operator dependence and limited reproducibility. A literature review of supplemental whole-breast US for screening was performed, which showed that both AB US and handheld US allow detection of mammographically negative early-stage invasive breast cancers but also increase the false-positive recall rate. Technicians with limited training can perform AB US; nevertheless, there is a learning curve for acquiring optimal images. Proper acquisition technique may allow avoidance of common artifacts that could impair interpretation of AB US results. Regardless, interpretation of AB US results can be challenging. This article reviews the US appearance of common benign and malignant lesions and presents examples of false-positive and false-negative AB US results. In situ breast cancers are rarely detected with supplemental whole-breast US. The most discriminating feature that separates AB US from handheld US is the retraction phenomenon on coronal reformatted images. The retraction phenomenon is rarely seen with benign findings but accompanies almost all breast cancers. In conclusion, women with dense breasts may benefit from supplemental AB US examinations. Understanding the pitfalls in acquisition technique and lesion interpretation, both of which can lead to false-positive recalls, might reduce the potential harm of performing supplemental AB US. Online supplemental material is available for this article. ©RSNA, 2018.
- Open Access
- 7 February 2018
- Published by Springer Nature in European Radiology
- Vol. 28 (7) , 2996-3006
Dedicated computer-aided detection software for automated 3D breast ultrasound; an efficient tool for the radiologist in supplemental screening of women with dense breasts
Objectives To determine the effect of computer-aided-detection (CAD) software for automated breast ultrasound (ABUS) on reading time (RT) and performance in screening for breast cancer. Material and methods Unilateral ABUS examinations of 120 women with dense breasts were randomly selected from a multi-institutional archive of cases including 30 malignant (20/30 mammography-occult), 30 benign, and 60 normal cases with histopathological verification or ≥ 2 years of negative follow-up. Eight radiologists read once with (CAD-ABUS) and once without CAD (ABUS) with > 8 weeks between reading sessions. Readers provided a BI-RADS score and a level of suspiciousness (0-100). RT, sensitivity, specificity, PPV and area under the curve (AUC) were compared. Results Average RT was significantly shorter using CAD-ABUS (133.4 s/case, 95% CI 129.2-137.6) compared with ABUS (158.3 s/case, 95% CI 153.0-163.3) (p < 0.001). Sensitivity was 0.84 for CAD-ABUS (95% CI 0.79-0.89) and ABUS (95% CI 0.78-0.88) (p = 0.90). Three out of eight readers showed significantly higher specificity using CAD. Pooled specificity (0.71, 95% CI 0.68-0.75 vs. 0.67, 95% CI 0.64-0.70, p = 0.08) and PPV (0.50, 95% CI 0.45-0.55 vs. 0.44, 95% CI 0.39-0.49, p = 0.07) were higher in CAD-ABUS vs. ABUS, respectively, albeit not significantly. Pooled AUC for CAD-ABUS was comparable with ABUS (0.82 vs. 0.83, p = 0.53, respectively). Conclusion CAD software for ABUS may decrease the time needed to screen for breast cancer without compromising the screening performance of radiologists. Key Points • ABUS with CAD software may speed up reading time without compromising radiologists’ accuracy. • CAD software for ABUS might prevent non-detection of malignant breast lesions by radiologists. • Radiologists reading ABUS with CAD software might improve their specificity without losing sensitivity.
- 7 February 2018
- Published by Springer Nature in European Radiology
- Vol. 28 (7) , 2996-3006
Open AccessDedicated computer-aided detection software for automated 3D breast ultrasound; an efficient tool for the radiologist in supplemental screening of women with dense breasts
Objectives To determine the effect of computer-aided-detection (CAD) software for automated breast ultrasound (ABUS) on reading time (RT) and performance in screening for breast cancer. Material and methods Unilateral ABUS examinations of 120 women with dense breasts were randomly selected from a multi-institutional archive of cases including 30 malignant (20/30 mammography-occult), 30 benign, and 60 normal cases with histopathological verification or ≥ 2 years of negative follow-up. Eight radiologists read once with (CAD-ABUS) and once without CAD (ABUS) with > 8 weeks between reading sessions. Readers provided a BI-RADS score and a level of suspiciousness (0-100). RT, sensitivity, specificity, PPV and area under the curve (AUC) were compared. Results Average RT was significantly shorter using CAD-ABUS (133.4 s/case, 95% CI 129.2-137.6) compared with ABUS (158.3 s/case, 95% CI 153.0-163.3) (p < 0.001). Sensitivity was 0.84 for CAD-ABUS (95% CI 0.79-0.89) and ABUS (95% CI 0.78-0.88) (p = 0.90). Three out of eight readers showed significantly higher specificity using CAD. Pooled specificity (0.71, 95% CI 0.68-0.75 vs. 0.67, 95% CI 0.64-0.70, p = 0.08) and PPV (0.50, 95% CI 0.45-0.55 vs. 0.44, 95% CI 0.39-0.49, p = 0.07) were higher in CAD-ABUS vs. ABUS, respectively, albeit not significantly. Pooled AUC for CAD-ABUS was comparable with ABUS (0.82 vs. 0.83, p = 0.53, respectively). Conclusion CAD software for ABUS may decrease the time needed to screen for breast cancer without compromising the screening performance of radiologists. Key Points • ABUS with CAD software may speed up reading time without compromising radiologists’ accuracy. • CAD software for ABUS might prevent non-detection of malignant breast lesions by radiologists. • Radiologists reading ABUS with CAD software might improve their specificity without losing sensitivity.
- 1 November 2017
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 285 (2) , 376-388
Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography
Supplemental three-dimensional automated breast US twice yearly does not lead to earlier or additional detection of breast cancer in carriers of the BRCA mutation and intensive surveillance of carriers of the BRCA mutation with dynamic contrast-enhanced MR imaging protocols also gain little from supplemental mammography in women under 40 years. PurposeTo evaluate a multimodal surveillance regimen including yearly full-field digital (FFD) mammography, dynamic contrast agent–enhanced (DCE) magnetic resonance (MR) imaging, and biannual automated breast (AB) ultrasonography (US) in women with BRCA1 and BRCA2 mutations.Materials and MethodsThis prospective multicenter trial enrolled 296 carriers of the BRCA mutation (153 BRCA1 and 128 BRCA2 carriers, and 15 women with first-degree untested relatives) between September 2010 and November 2012, with follow-up until November 2015. Participants underwent 2 years of intensified surveillance including biannual AB US, and routine yearly DCE MR imaging and FFD mammography. The surveillance performance for each modality and possible combinations were determined.ResultsBreast cancer was screening-detected in 16 women (age range, 33–58 years). Three interval cancers were detected by self-examination, all in carriers of the BRCA1 mutation under age 43 years. One cancer was detected in a carrier of the BRCA1 mutat...
- 1 November 2017
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 285 (2) , 376-388
Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography
Supplemental three-dimensional automated breast US twice yearly does not lead to earlier or additional detection of breast cancer in carriers of the BRCA mutation and intensive surveillance of carriers of the BRCA mutation with dynamic contrast-enhanced MR imaging protocols also gain little from supplemental mammography in women under 40 years. PurposeTo evaluate a multimodal surveillance regimen including yearly full-field digital (FFD) mammography, dynamic contrast agent–enhanced (DCE) magnetic resonance (MR) imaging, and biannual automated breast (AB) ultrasonography (US) in women with BRCA1 and BRCA2 mutations.Materials and MethodsThis prospective multicenter trial enrolled 296 carriers of the BRCA mutation (153 BRCA1 and 128 BRCA2 carriers, and 15 women with first-degree untested relatives) between September 2010 and November 2012, with follow-up until November 2015. Participants underwent 2 years of intensified surveillance including biannual AB US, and routine yearly DCE MR imaging and FFD mammography. The surveillance performance for each modality and possible combinations were determined.ResultsBreast cancer was screening-detected in 16 women (age range, 33–58 years). Three interval cancers were detected by self-examination, all in carriers of the BRCA1 mutation under age 43 years. One cancer was detected in a carrier of the BRCA1 mutat...
- 1 October 2017
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 52 (10) , 574-582
Compressed Sensing for Breast MRI: Resolving the Trade-Off Between Spatial and Temporal Resolution
Objective: Ultrafast dynamic contrast-enhanced magnetic resonance imaging of the breast enables assessment of the contrast inflow dynamics while providing images with diagnostic spatial resolution. However, the slice thickness of common ultrafast techniques still prevents multiplanar reconstruction. In addition, some temporal blurring of the enhancement characteristics occurs in case view-sharing is used. We evaluate a prototype compressed-sensing volume-interpolated breath-hold examination (CS-VIBE) sequence for ultrafast breast MRI that improves through plane spatial resolution and avoids temporal blurring while maintaining an ultrafast temporal resolution (less than 5 seconds per volume). Image quality (IQ) of the new sequence is compared with an ultrafast view-sharing sequence (time-resolved angiography with interleaved stochastic trajectories [TWIST]), and assessment of lesion morphology is compared with a regular T1-weighted 3D Dixon sequence (VIBE-DIXON) with an acquisition time of 91 seconds. Materials and Methods: From April 2016 to October 2016, 30 women were scanned with the CS-VIBE sequence, replacing the routine ultrafast TWIST sequence in a hybrid breast MRI protocol. The need for informed consent was waived. All MRI scans were performed on a 3T MAGNETOM Skyra system (Siemens Healthcare, Erlangen, Germany) using a 16-channel bilateral breast coil. Two reader studies were conducted involving 5 readers. In the first study, overall IQ of CS-VIBE and TWIST in the axial plane was independently rated for 23 women for whom prior MRI examinations with TWIST were available. In addition, the presence of several types of artifacts was rated on a 5-point scale. The second study was conducted in women (n = 16) with lesions. In total, characteristics of 31 lesions (5 malignant and 26 benign) were described independently for CS-VIBE and VIBE-DIXON, according to the BI-RADS MRI-lexicon. In addition, a lesion conspicuity score was given. Results: Using CS-VIBE, a much higher through-plane spatial resolution was achieved in the same acquisition time as with TWIST, without affecting in-plane IQ (P = 0.260). Time-resolved angiography with interleaved stochastic trajectories showed slightly more motion artifacts and infolding and ghosting artifacts compared with CS-VIBE, whereas CS-VIBE showed more breathing and pulsation artifacts. For morphologic assessment, intrareader agreement between CS-VIBE and the more time-consuming VIBE-DIXON was slight to almost perfect, and generally higher than interreader agreement. Mean sensitivity (84.0% and 92.0% for CS-VIBE and VIBE-DIXON, P = 0.500) and specificity (60.0% and 55.4% for CS-VIBE and VIBE-DIXON, P = 0.327) were comparable for both sequences. Conclusions: Compressed-sensing volume-interpolated breath-hold examination allows an increase of the through-plane spatial resolution of ultrafast dynamic contrast-enhanced magnetic resonance imaging compared with TWIST at a comparable in-plane IQ. Morphological assessment of lesions using CS-VIBE is comparable to VIBE-DIXON, which takes 18 times longer. Consequently, CS-VIBE enables 3D evaluation of breast lesions in ultrafast breast MRI.
- 1 October 2017
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 52 (10) , 574-582
Compressed Sensing for Breast MRI: Resolving the Trade-Off Between Spatial and Temporal Resolution
Objective: Ultrafast dynamic contrast-enhanced magnetic resonance imaging of the breast enables assessment of the contrast inflow dynamics while providing images with diagnostic spatial resolution. However, the slice thickness of common ultrafast techniques still prevents multiplanar reconstruction. In addition, some temporal blurring of the enhancement characteristics occurs in case view-sharing is used. We evaluate a prototype compressed-sensing volume-interpolated breath-hold examination (CS-VIBE) sequence for ultrafast breast MRI that improves through plane spatial resolution and avoids temporal blurring while maintaining an ultrafast temporal resolution (less than 5 seconds per volume). Image quality (IQ) of the new sequence is compared with an ultrafast view-sharing sequence (time-resolved angiography with interleaved stochastic trajectories [TWIST]), and assessment of lesion morphology is compared with a regular T1-weighted 3D Dixon sequence (VIBE-DIXON) with an acquisition time of 91 seconds. Materials and Methods: From April 2016 to October 2016, 30 women were scanned with the CS-VIBE sequence, replacing the routine ultrafast TWIST sequence in a hybrid breast MRI protocol. The need for informed consent was waived. All MRI scans were performed on a 3T MAGNETOM Skyra system (Siemens Healthcare, Erlangen, Germany) using a 16-channel bilateral breast coil. Two reader studies were conducted involving 5 readers. In the first study, overall IQ of CS-VIBE and TWIST in the axial plane was independently rated for 23 women for whom prior MRI examinations with TWIST were available. In addition, the presence of several types of artifacts was rated on a 5-point scale. The second study was conducted in women (n = 16) with lesions. In total, characteristics of 31 lesions (5 malignant and 26 benign) were described independently for CS-VIBE and VIBE-DIXON, according to the BI-RADS MRI-lexicon. In addition, a lesion conspicuity score was given. Results: Using CS-VIBE, a much higher through-plane spatial resolution was achieved in the same acquisition time as with TWIST, without affecting in-plane IQ (P = 0.260). Time-resolved angiography with interleaved stochastic trajectories showed slightly more motion artifacts and infolding and ghosting artifacts compared with CS-VIBE, whereas CS-VIBE showed more breathing and pulsation artifacts. For morphologic assessment, intrareader agreement between CS-VIBE and the more time-consuming VIBE-DIXON was slight to almost perfect, and generally higher than interreader agreement. Mean sensitivity (84.0% and 92.0% for CS-VIBE and VIBE-DIXON, P = 0.500) and specificity (60.0% and 55.4% for CS-VIBE and VIBE-DIXON, P = 0.327) were comparable for both sequences. Conclusions: Compressed-sensing volume-interpolated breath-hold examination allows an increase of the through-plane spatial resolution of ultrafast dynamic contrast-enhanced magnetic resonance imaging compared with TWIST at a comparable in-plane IQ. Morphological assessment of lesions using CS-VIBE is comparable to VIBE-DIXON, which takes 18 times longer. Consequently, CS-VIBE enables 3D evaluation of breast lesions in ultrafast breast MRI.
- 1 September 2017
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 43 (9) , 1820-1828
Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound
- 1 September 2017
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 43 (9) , 1820-1828
Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound
- 1 April 2017
- Published by Elsevier in European Journal of Radiology
- Vol. 89, 54-59
Improved cancer detection in automated breast ultrasound by radiologists using Computer Aided Detection
- 1 April 2017
- Published by Elsevier in European Journal of Radiology
- Vol. 89, 54-59
Improved cancer detection in automated breast ultrasound by radiologists using Computer Aided Detection
- 1 March 2017
- Published by Elsevier in European Journal of Radiology
- Vol. 88, 141-147
3D quantitative breast ultrasound analysis for differentiating fibroadenomas and carcinomas smaller than 1 cm
- 1 March 2017
- Published by Elsevier in European Journal of Radiology
- Vol. 88, 141-147
3D quantitative breast ultrasound analysis for differentiating fibroadenomas and carcinomas smaller than 1 cm